LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 2094

Search options

  1. Article ; Online: Composite predictive models for asthma exacerbations or asthma deterioration in pediatric asthmatic patients: A systematic review of the literature.

    Rodríguez-Martínez, Carlos E / Sossa-Briceño, Monica P / Forno, Erick

    Pediatric pulmonology

    2023  Volume 58, Issue 10, Page(s) 2703–2718

    Abstract: A variety of factors have shown to be useful in predicting which children are at high risk for future asthma exacerbations, some of them combined into composite predictive models. The objective of the present review was to systematically identify all the ...

    Abstract A variety of factors have shown to be useful in predicting which children are at high risk for future asthma exacerbations, some of them combined into composite predictive models. The objective of the present review was to systematically identify all the available published composite predictive models developed for predicting which children are at high risk for future asthma exacerbations or asthma deterioration. A systematic search of the literature was performed to identify studies in which a composite predictive model developed for predicting which children are at high risk for future asthma exacerbations or asthma deterioration was described. Methodological quality assessment was performed using accepted criteria for prediction rules and prognostic models. A total of 18 articles, describing a total of 17 composite predictive models were identified and included in the review. The number of predictors included in the models ranged from 2-149. Upon analyzing the content of the models, use of healthcare services for asthma and prescribed or dispensed asthma medications were the most frequently used items (in 8/17, 47.0% of the models). Seven (41.2%) models fulfilled all the quality criteria considered in our evaluation. The identified models may help clinicians dealing with asthmatic children to identify which children are at a higher risk for future asthma exacerbations or asthma deterioration, therefore targeting and/or reinforcing specific interventions for these children in an attempt to prevent exacerbations or deterioration of the disease.
    MeSH term(s) Child ; Humans ; Anti-Asthmatic Agents/therapeutic use ; Disease Progression ; Asthma/drug therapy ; Asthma/epidemiology
    Chemical Substances Anti-Asthmatic Agents
    Language English
    Publishing date 2023-07-05
    Publishing country United States
    Document type Systematic Review ; Journal Article ; Review
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26584
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Exploratory analysis of the economically justifiable price of nirsevimab for healthy late-preterm and term infants in Colombia.

    Buendía, Jefferson Antonio / Acuña-Cordero, Ranniery / Rodriguez-Martinez, Carlos E

    Pediatric pulmonology

    2024  

    Abstract: Introduction: Respiratory syncytial virus infection is the leading cause of lower respiratory infection globally. Recently, nirsevimab has been approved to prevent respiratory syncytial virus (RSV) infection. This study explores the economically ... ...

    Abstract Introduction: Respiratory syncytial virus infection is the leading cause of lower respiratory infection globally. Recently, nirsevimab has been approved to prevent respiratory syncytial virus (RSV) infection. This study explores the economically justifiable price of nirsevimab for preventing RSV infection in Colombia's children under 1 year of age.
    Materials and methods: A static model was developed using the decision tree microsimulation to estimate the quality-adjusted costs and life years of two interventions: a single intramuscular dose of nirsevimab versus not applying nirsevimab. This analysis was made during a time horizon of 1 year and from a societal perspective.
    Results: The annual savings in Colombia associated with this cost per dose ranged from U$ 2.5 to 4.1 million. Based on thresholds of U$ 4828, U$ 5128, and U$ 19 992 per QALY evaluated in this study, we established economically justifiable drug acquisition prices of U$ 21.88, U$ 25.04, and U$ 44.02 per dose of nirsevimab.
    Conclusion: the economically justifiable cost for nirsevimab in Colombia is between U$ 21 to U$ 44 per dose, depending on the willingness to pay used to decide its implementation. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.
    Language English
    Publishing date 2024-02-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26920
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: As-Needed Use of Short-Acting β

    Rodríguez-Martínez, Carlos E / Sossa-Briceño, Monica P / Buendia, Jefferson Antonio

    The journal of allergy and clinical immunology. In practice

    2022  Volume 10, Issue 6, Page(s) 1562–1568

    Abstract: Background: Although the efficacy of the as-needed use of short-acting β: Objectives: The aim of the present study was to compare the cost-effectiveness of the as-needed use of SABAs alone versus the as-needed use of SABAs plus ICS in children 5 to ... ...

    Abstract Background: Although the efficacy of the as-needed use of short-acting β
    Objectives: The aim of the present study was to compare the cost-effectiveness of the as-needed use of SABAs alone versus the as-needed use of SABAs plus ICS in children 5 to 11 years old with mild intermittent (step 1) asthma but suffering from an exacerbation of asthma symptoms.
    Methods: A decision-analysis model was adapted. Effectiveness parameters were obtained from a randomized clinical trial. Cost data were obtained from hospital bills and from the national manual of drug prices in Colombia. The study was carried out from the perspective of the national health care system in Colombia. The main outcome of the model was a first course of prednisone for an asthma exacerbation (AE).
    Results: Compared with the use of SABAs alone, the as-needed use of SABAs plus ICS was associated with lower overall treatment costs (US$17.99 vs US$27.94 mean cost per patient) and a higher probability of a lack of a requirement for a first course of prednisone (0.6500 vs 0.5100), thus showing dominance.
    Conclusions: In Colombia, compared with the use of albuterol alone, the use of beclomethasone dipropionate added to albuterol as needed for symptom relief is cost-effective in children 5 to 11 years old with mild intermittent (step 1) asthma, because it involves a higher probability of a lack of a requirement for prednisone for AE at lower total treatment costs.
    MeSH term(s) Administration, Inhalation ; Adrenal Cortex Hormones ; Albuterol/therapeutic use ; Anti-Asthmatic Agents/therapeutic use ; Asthma/drug therapy ; Child ; Child, Preschool ; Cost-Benefit Analysis ; Drug Therapy, Combination ; Humans ; Hyperplasia/drug therapy ; Prednisone/therapeutic use
    Chemical Substances Adrenal Cortex Hormones ; Anti-Asthmatic Agents ; Albuterol (QF8SVZ843E) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2022-03-05
    Publishing country United States
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2022.02.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Emergency department-initiated home oxygen for viral bronchiolitis: A cost-effectiveness analysis.

    Rodríguez-Martínez, Carlos E / Sossa-Briceño, Monica P / Nino, Gustavo

    Pediatric pulmonology

    2022  Volume 57, Issue 9, Page(s) 2154–2160

    Abstract: Objective: The use of emergency department (ED)-initiated outpatient oxygen therapy has been considered to be a possible alternative to hospitalization for otherwise healthy-appearing, well-hydrated infants with uncomplicated disease. However, a formal ... ...

    Abstract Objective: The use of emergency department (ED)-initiated outpatient oxygen therapy has been considered to be a possible alternative to hospitalization for otherwise healthy-appearing, well-hydrated infants with uncomplicated disease. However, a formal economic evaluation of this treatment strategy is lacking. The aim of the present study was to compare the cost-effectiveness of ED-initiated outpatient oxygen therapy versus conventional inpatient hospitalization in infants with uncomplicated hypoxic bronchiolitis living in Bogota, the high-altitude capital city of Colombia, a middle-income country (MIC).
    Methods: A decision analysis model was developed to estimate the cost-effectiveness of ED-initiated outpatient oxygen therapy versus hospitalization. The main outcome of the model was avoidance of admission to a high-dependency unit.
    Results: Compared to hospitalization, ED-initiated outpatient oxygen therapy was associated with lower total costs (US$306.7 vs. US$638.7 average cost per patient) and a higher probability of avoidance of admission to a high-dependency unit (0.9528 vs. 0.8960), thus leading to dominance. The results were robust to deterministic and probabilistic sensitivity analyses.
    Conclusions: Our study suggests that in infants attending the ED with an uncomplicated hypoxic bronchiolitis episode in the city of Bogota, a high-altitude city, ED-initiated outpatient oxygen therapy is a dominant strategy compared to conventional inpatient hospitalization, because it involves a higher probability of avoidance of admission to a high-dependency unit, at lower total treatment costs.
    MeSH term(s) Bronchiolitis/therapy ; Bronchiolitis, Viral/therapy ; Cost-Benefit Analysis ; Emergency Service, Hospital ; Hospitalization ; Humans ; Infant ; Oxygen
    Chemical Substances Oxygen (S88TT14065)
    Language English
    Publishing date 2022-06-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Disparities in prevalence and outcomes of respiratory disease in low- and middle-income countries.

    Rodriguez-Martinez, Carlos E / Sossa-Briceño, Monica P

    Pediatric pulmonology

    2023  

    Abstract: Objectives: To provide a comprehensive overview of disparities in prevalence and outcomes of respiratory diseases and notable challenges for providing optimal treatment to pediatric patients with respiratory diseases living in low- and middle-income ... ...

    Abstract Objectives: To provide a comprehensive overview of disparities in prevalence and outcomes of respiratory diseases and notable challenges for providing optimal treatment to pediatric patients with respiratory diseases living in low- and middle-income countries (LMICs), as an input to help better understand the roots of respiratory health disparities.
    Methods: We conducted a narrative review of relevant literature published in electronic databases from inception to February 2023 that present data on disparities in prevalence and outcomes of respiratory disease in LMICs. Additionally, we included studies that describe and discuss challenges for providing optimal treatment to pediatric patients with respiratory diseases living in LMICs.
    Results: A number of early life exposures have been associated with adverse respiratory outcomes in later life. Several studies have shown marked geographical variations in the prevalence and burden of pediatric asthma, with consistently lower prevalence rates but significantly higher burdens and worse outcomes in LMICs. There is a wide range of challenges that adversely affect the efficient care of children with respiratory diseases that can be classified into three categories: patient-related factors, social/environmental factors, and factors related to healthcare providers or the healthcare system.
    Conclusions: Respiratory health disparities in children living in LMICs represent a global public health issue mainly explained by an unequal distribution of preventable and modifiable risk factors for respiratory diseases across different demographic groups.
    Language English
    Publishing date 2023-06-28
    Publishing country United States
    Document type Journal Article
    ZDB-ID 632784-9
    ISSN 1099-0496 ; 8755-6863
    ISSN (online) 1099-0496
    ISSN 8755-6863
    DOI 10.1002/ppul.26573
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Budesonide/formoterol as maintenance and reliever therapy compared to fixed-budesonide/formoterol plus albuterol reliever for pediatric asthma: A cost-utility analysis in Colombia.

    Rodríguez-Martínez, Carlos E / Sossa-Briceño, Monica P / Nino, Gustavo

    The journal of allergy and clinical immunology. In practice

    2021  Volume 9, Issue 10, Page(s) 3816–3818.e2

    MeSH term(s) Administration, Inhalation ; Albuterol/therapeutic use ; Asthma/drug therapy ; Bronchodilator Agents/therapeutic use ; Budesonide/therapeutic use ; Child ; Colombia ; Cost-Benefit Analysis ; Drug Combinations ; Ethanolamines/therapeutic use ; Formoterol Fumarate/therapeutic use ; Humans
    Chemical Substances Bronchodilator Agents ; Drug Combinations ; Ethanolamines ; Budesonide (51333-22-3) ; Albuterol (QF8SVZ843E) ; Formoterol Fumarate (W34SHF8J2K)
    Language English
    Publishing date 2021-06-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2021.05.023
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: To the Editor.

    Restrepo-Gualteros, Sonia / Villamil-Osorio, Milena / Rodríguez-Martínez, Carlos E

    Sleep medicine

    2021  Volume 86, Page(s) 124

    Language English
    Publishing date 2021-05-24
    Publishing country Netherlands
    Document type Letter ; Comment
    ZDB-ID 2012041-2
    ISSN 1878-5506 ; 1389-9457
    ISSN (online) 1878-5506
    ISSN 1389-9457
    DOI 10.1016/j.sleep.2021.05.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Oxygen saturation thresholds for bronchiolitis at high altitudes: a cost-effectiveness analysis.

    Rodriguez-Martinez, Carlos E / Sossa-Briceño, Monica P / Nino, Gustavo

    Expert review of pharmacoeconomics & outcomes research

    2023  Volume 23, Issue 5, Page(s) 527–533

    Abstract: Background: There is evidence suggesting that exaggerated reliance on pulse oximetry (SpO2) and the use of arbitrary/inadequate thresholds of SpO2 might drive unnecessary hospitalizations for viral bronchiolitis, especially among high-altitude residents. ...

    Abstract Background: There is evidence suggesting that exaggerated reliance on pulse oximetry (SpO2) and the use of arbitrary/inadequate thresholds of SpO2 might drive unnecessary hospitalizations for viral bronchiolitis, especially among high-altitude residents. The aim of the present study was to compare the cost-effectiveness of two oxygen SpO2 thresholds for deciding whether infants with viral bronchiolitis living at high altitudes need hospital admission or can be discharged home.
    Methods: A cost-effectiveness study was performed to compare the cost and clinical outcomes of two oxygen SpO2 thresholds, adjusted or not, to an altitude above the sea level of Bogota, Colombia (2640 m), for deciding whether infants with viral bronchiolitis need hospitalization or can be discharged home. The principal outcome was avoidance of hospital admission.
    Results: Compared to the use of an SpO2 threshold of 90%, using an SpO2 threshold of 85% in infants with viral bronchiolitis was associated with lower overall costs (US$130.4 vs. US$194.0 average cost per patient) and a higher probability of hospitalization avoided (0.7500 vs. 0.5900), thus leading to dominance.
    Conclusions: The use of an SpO2 threshold below 90% for deciding on hospitalization in infants with viral bronchiolitis living at high altitudes appears to be logical, secure, and cost-effective.
    MeSH term(s) Infant ; Humans ; Bronchiolitis, Viral ; Oxygen Saturation ; Altitude ; Cost-Effectiveness Analysis ; Oxygen ; Bronchiolitis/therapy
    Chemical Substances Oxygen (S88TT14065)
    Language English
    Publishing date 2023-03-20
    Publishing country England
    Document type Journal Article
    ZDB-ID 2208481-2
    ISSN 1744-8379 ; 1473-7167
    ISSN (online) 1744-8379
    ISSN 1473-7167
    DOI 10.1080/14737167.2023.2192482
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Customizable orodispersible films: Inkjet printing and data matrix encoding for personalized hydrocortisone dosing.

    Rodríguez-Pombo, Lucía / Carou-Senra, Paola / Rodríguez-Martínez, Erea / Januskaite, Patricija / Rial, Carlos / Félix, Paulo / Alvarez-Lorenzo, Carmen / Basit, Abdul W / Goyanes, Alvaro

    International journal of pharmaceutics

    2024  Volume 655, Page(s) 124005

    Abstract: The aim of this study was to exploit the versatility of inkjet printing to develop flexible doses of drug-loaded orodispersible films that encoded information in a data matrix pattern, and to introduce a specialised data matrix-generator software ... ...

    Abstract The aim of this study was to exploit the versatility of inkjet printing to develop flexible doses of drug-loaded orodispersible films that encoded information in a data matrix pattern, and to introduce a specialised data matrix-generator software specifically focused on the healthcare sector. Pharma-inks (drug-loaded inks) containing hydrocortisone (HC) were developed and characterised based on their rheological properties and drug content. Different strategies were investigated to improve HC solubility: formation of β-cyclodextrin complexes, Soluplus® based micelles, and the use of co-solvent systems. The software automatically adapted the data matrix size and identified the number of layers for printing. HC content deposited in each film layer was measured, and it was found that the proportion of co-solvent used directly affected the drug solubility and simultaneously played a role in the modification of the viscosity and surface tension of the inks. The formation of β-cyclodextrin complexes improved the drug quantity deposited in each layer. On the contrary, micelle-based inks were not suitable for printing. Orodispersible films containing flexible and low doses of personalised HC were successfully prepared, and the development of a code generator software oriented to medical use provided an additional, innovative, and revolutionary advantage to personalised medicine safety and accessibility.
    MeSH term(s) Hydrocortisone ; Solvents ; Micelles ; Printing ; beta-Cyclodextrins
    Chemical Substances Hydrocortisone (WI4X0X7BPJ) ; Solvents ; Micelles ; beta-Cyclodextrins
    Language English
    Publishing date 2024-03-15
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 428962-6
    ISSN 1873-3476 ; 0378-5173
    ISSN (online) 1873-3476
    ISSN 0378-5173
    DOI 10.1016/j.ijpharm.2024.124005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Human neonatal and infant airway epithelial biology: the new frontier for developmental immunology.

    Nino, Gustavo / Gutierrez, Maria J / Rodriguez-Martinez, Carlos E

    Expert review of respiratory medicine

    2022  Volume 16, Issue 2, Page(s) 145–147

    MeSH term(s) Biology ; Humans ; Infant ; Infant, Newborn
    Language English
    Publishing date 2022-02-10
    Publishing country England
    Document type Editorial ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2479146-5
    ISSN 1747-6356 ; 1747-6348
    ISSN (online) 1747-6356
    ISSN 1747-6348
    DOI 10.1080/17476348.2022.2027757
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top